Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05682144 · ClinicalTrials.gov registry record · Phase 1
ISP-001: Sleeping Beauty Transposon-Engineered B Cells for MPS I
A Phase 1 study of Mucopolysaccharidosis IH/S and Mucopolysaccharidosis IS, sponsored by Immusoft of CA.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
- 2
- Study locations
NCT05682144: Recruiting Phase 1 study of Mucopolysaccharidosis IH/S and Mucopolysaccharidosis IS, sponsored by Immusoft of CA.
NCT05682144 is a Phase 1 study of Mucopolysaccharidosis IH/S and Mucopolysaccharidosis IS that is actively recruiting participants, run by Immusoft of CA. The registered enrollment target is 2 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05682144, a Phase 1 study of Mucopolysaccharidosis IH/S and Mucopolysaccharidosis IS, is actively recruiting participants, sponsored by Immusoft of CA.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
- 2
- Study locations
Study Summary
A first-in-human study using ISP-001 in adult patients with Mucopolysaccharidosis Type I Hurler-Scheie and Scheie.
Primary Outcome
Incidence of Adverse Events as assessed by CTCAE (v 5.0)
Conditions Studied
Interventions
- BIOLOGICAL Autologous Plasmablasts (B cells)
Study Locations (2)
California
- UCSF Benioff Children's Hospital Oakland - Oakland
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2023-04-12 |
| Est. Completion | 2039-06-01 |
| Phase | Phase 1 |
What NCT05682144 shows while recruiting
NCT05682144 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Mucopolysaccharidosis IH/S appearing as the primary indexed condition, and to 1 intervention - of which Autologous Plasmablasts (B cells) is the first listed.
NCT05682144 reports a single indexed study location in California, Minnesota.
Frequently Asked Questions
What is clinical trial NCT05682144 about?
NCT05682144 is a clinical study titled "ISP-001: Sleeping Beauty Transposon-Engineered B Cells for MPS I". A first-in-human study using ISP-001 in adult patients with Mucopolysaccharidosis Type I Hurler-Scheie and Scheie.
What is the current status of trial NCT05682144?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2023-04-12. Estimated completion is 2039-06-01.
What conditions does trial NCT05682144 study?
This clinical trial studies the following conditions: Mucopolysaccharidosis IH/S, Mucopolysaccharidosis IS.
What interventions are being tested in trial NCT05682144?
The interventions under investigation include: Autologous Plasmablasts (B cells) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05682144?
This trial is sponsored by Immusoft of CA, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05682144 being conducted?
This trial has 2 study locations across California, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05682144's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI